Active Filter(s):
Details:
Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Immedica Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 24, 2023
Details:
AKYNZEO (Netupitant) is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Akynzeo is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Helsinn Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 28, 2022